Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals acquired Azora Therapeutics and secured up to $64 million in financing to advance AT177, a colon-targeted AhR agonist for ulcerative colitis treatment. The deal includes $32 million upfront and potential $32 million in milestone-based funding, with Phase 1 clinical trials planned for mid-2027. The company also appointed Wendy Young, Ph.D. to its Board of Directors.